Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells

Douglas B. Kell* and Etheresia Pretorius*

"Serum ferritin" presents a paradox, as the iron storage protein ferritin is not synthesised in serum yet is to be found there. Serum ferritin is also a well known inflammatory marker, but it is unclear whether serum ferritin reflects or causes inflammation, or whether it is involved in an inflammatory cycle. We argue here that serum ferritin arises from damaged cells, and is thus a marker of cellular damage. The protein in serum ferritin is considered benign, but it has lost (i.e. dumped) most of its normal complement of iron which when unliganded is highly toxic. The facts that serum ferritin levels can correlate with both disease and with body iron stores are thus expected on simple chemical kinetic grounds. Serum ferritin levels also correlate with other phenotypic readouts such as erythrocyte morphology. Overall, this systems approach serves to explain a number of apparent paradoxes of serum ferritin, including (i) why it correlates with biomarkers of cell damage, (ii) why it correlates with biomarkers of hydroxyl radical formation (and oxidative stress) and (iii) therefore why it correlates with the presence and/or severity of numerous diseases. This leads to suggestions for how one might exploit the corollaries of the recognition that serum ferritin levels mainly represent a consequence of cell stress and damage.

Introduction

In mammals (in contrast, for instance, to some functions in insects1–4), ferritin is supposed to be a cellular means of storing iron,5 not of transporting it, yet serum ferritin levels are widely measured as indicators of iron status. However, the soluble transferrin receptor (sTfR) : log ferritin ratio (sTfR Index) probably provides a better estimate of body iron over a wide range of normal and depleted iron stores.6–9 This is because serum ferritin levels can be raised significantly in response to inflammation and/or a variety of diseases (see later). "Serum ferritin" thus presents something of a paradox. Taking a systems approach, we develop and summarise the view that "serum ferritin" actually originates from damaged cells (and thus reflects cellular damage), that it contains some iron but has lost or liberated most of its normal content, and that since the protein part of ferritin is assumed to be benign, that it is this (initially) free iron that correlates with and is causative of disease. The rest of this analytical and synthetic review summarises the wide-ranging evidence for this. We necessarily start by reviewing iron metabolism from a systems point of view (Fig. 1).

A systems biology overview of human iron metabolism

A starting point for systems biology is the creation of the network (mathematically a ‘graph’) of interacting partners (e.g. ref. 10–14). To this end, a number of recent genomic-level or systems biology reviews have summarised the chief features of human iron metabolism (e.g. ref. 15–19). (Systems genetics analyses are also available. 20–23) For the present purposes, aimed at seeking the ‘function’ of human serum ferritin (SF), we shall take a particularly high level view, and assume that the body has a very restricted number of compartments. Fig. 2, updated from ref. 15 shows essentially just three: intestinal tissue, peripheral tissue and blood/serum, and (see also ref. 24, 25 and cf. ref. 26) these will be quite sufficient.

Thus, as is well known, ferric salts and ions are poorly water soluble (hence the need for siderophores – better known in microbiology27–30), and much of the complex (redox) chemistry of iron in the body is designed to deal with this. In addition to its existence in divalent and trivalent states, iron is also capable...
of being liganded in up to 6 places (4 equatorial, 2 polar), and this liganding is necessary to stop its otherwise exceptional reactivity, specifically the production of the very damaging hydroxyl radical that reacts in nanoseconds with the nearest biological substances via the Fenton reaction of H₂O₂ and Fe(n). This may be coupled to the re-reduction of Fe(n) to Fe(II) by superoxide in the Haber–Weiss reaction, such that unliganded (or poorly liganded) iron moieties are catalytic and thus especially dangerous. Thus, while iron is vital for living processes, there is an exceptionally important need to sequester iron in a suitably liganded form, and cellular ferritin is a major means of doing this.

Leaving aside haem, and also nutrient-derived ferritins, iron is absorbed in the intestine as ferrous ions and transported in the serum bound (in the ferric form) to transferrin, where it can enter peripheral tissues via suitable receptors, being re-reduced in the process. Ferrous iron is incorporated into ferritin, simultaneously being oxidised at a di-iron centre to ferric iron. Thus, importantly, ferritin is made in cells (including intestinal cells), and not in serum. We also note the evidence for the presence of ferritin within erythrocytes, whereas the light subunit (L also standing for Lacks catalysis) facilitates the storage of iron into the ferritin core. Many X-ray structures are known. Broadly, each subunit consists of a 4-helix bundle, and their self-assembly (whether iron is present or not) is energetically extremely favourable – the melting or denaturation temperature of the 24mer cage is some 40°C greater than that of an individual subunit.

Iron loading mechanism of ferritin

The main features of the typical 24-subunit ferritin architecture (shown as an all-H-chain variant) are given in Fig. 4. Human ferritin is some 12 nm diameter overall, with a 2 nm thick protein shell and a hollow internal 8 nm diameter cavity capable of holding up to 4500 iron atoms. Ferrous ions can diffuse into (and out of) the core via the eight, hydrophilic 15–20 Å channels located at the 3-fold symmetry axis, where they are oxidised by dioxygen (or H₂O₂ if present) at a di-iron catalytic site to form Fe(n)₃-O products that then form the Fe₂O₃·H₂O mineral core. Other materials such as phosphate may also serve as counterions. Ferritin Fe₃O₄ nucleation channels open onto the internal surfaces of ferritin protein cages at the four-fold symmetry axes of the ferritin protein cage. The six channels located at the 4-fold axis of the protein are hydrophobic; their function does not seem to be known with any certainty, but they may permit entry of dioxygen and/or H₂O₂.

It is not quite so clear how (after storage as Fe(n) in the ferritin core) Fe(II) exits the channels to become available to cells, nor how the physiological (in vivo) reductant reaches the potential site of reduction inside the small channels. It is not clear even what the physiological reductant is, though NADH and FMN have been reported to serve, as have superoxide and other materials.

Douglas Kell is Research Professor in Bioanalytical Science at the University of Manchester, UK. His interests lie in systems biology, iron metabolism and dysregulation, cellular drug transporters, synthetic biology, e-science, chemometrics and cheminformatics. He was Director of the Manchester Centre for Integrative Systems Biology prior to a 5-year secondment (2008–2013) as Chief Executive of the UK Biotechnology and Biological Sciences Research Council. He is a Fellow of the Learned Society of Wales and of the American Association for the Advancement of Science, and was awarded a CBE for services to Science and Research in the New Year 2014 Honours list.

Etheresia Pretorius is a Research Professor in the Department of Physiology, Faculty of Health Sciences at the University of Pretoria, South Africa. Her interests lie in the ultrastructure and regulation of the human coagulation system, with particular focus on erythrocytes and fibrin networks, the role of iron metabolism and changes to the coagulation system due to inflammation. She is also Director of the Applied Morphology Research Centre of the University of Pretoria. She was chosen as the winner in 2011 of the African Union Kwame Nkrumah Scientific Awards Program: Women Scientist Regional Awards in the category Basic Science and Technology.
How much iron in cellular/tissue ferritin?

The number of iron atoms/ferritin cage is said to average 1000–1500 normally, governed more by iron availability than anything else, with a maximum of 4500 iron atoms normally being quoted (e.g., ref. 90–92, and attained for iron overload conditions or when loaded artificially in vitro). Direct observation also leads to a mode value of ~1500 in a liver biopsy from a patient with hereditary haemochromatosis.

What kind of ferritin in which tissues?

As mentioned, from a structural point of view in terms of forming the 24mer nanocage, ferritin H and L forms are interchangeable. Similarly, as expected, ferritin is expressed in most tissues. Thus, human protein atlas expression data for the light chain
http://www.proteinatlas.org/ENSG00000087086/normal show it mainly in CNS, bone marrow, spleen, liver, kidney, lung and adipocytes. Expression of the heavy chain is broadly similar to that in breast, uterus, testis, prostate and thyroid tissue. In terms of the actual stoichiometries of L:H in ferritin molecules in different tissues (which also affects the ordering or crystallinity of the mineral core\textsuperscript{73,47}) there is rather less information, and variations in this may be causative of disease.\textsuperscript{94,95} Clearly, for a 24-subunit molecule with two kinds of subunits, one can build 25 canonical ‘isoferritins’.\textsuperscript{74} Liver and spleen ferritin is mainly the L subunit while heart and brain ferritin is mainly the H subunit. Serum ferritin is mainly in the L form,\textsuperscript{5,96} consistent with the view that it typically originates in the liver.\textsuperscript{97} The same (i.e. mainly the L form) is presumably true for erythrocyte ferritin, in that this is what the usual ELISA tests for serum ferritin are designed to detect.

**Natural degradation of ferritin**

The exact circumstances under which ferritin is normally degraded in vivo (if it is intact) are not entirely clear, but what is clear is that there is a fundamental conceptual problem, in that if the only part degraded is the protein the result is the damaging liberation of unliganded iron. Certainly, as expected for normal cellular degradation, the proteasome is involved,\textsuperscript{38,98} but there is also a major lysosomal degradation pathway.\textsuperscript{38,99–103} We note too that overexpression can lead to the formation of ferritin inclusion bodies.\textsuperscript{104}

As well as proteolytic degradation, there are other means of ferritin removal. Thus, haemosiderin is an insoluble material formed from damaged ferritin (ferritin with exposed and potentially chemically reactive mineral sites), commonly appearing under conditions of iron overload and often reflecting a poorer disease prognosis (e.g. ref. 71, 105–112). (Note that another insoluble cellular degradation cluster – lipofuscin (e.g. ref. 113–116) – is different, as it does not contain haemosiderin.) However, the insoluble substance neuromelanin (e.g. ref. 115, 117–119) may contain ferritin or ferritin-like material.\textsuperscript{120–122} The question of what happens to haemosiderin seems rather poorly understood, but in contrast to ferritin it is not normally seen (nor at least measured) in serum;\textsuperscript{123,124} since it is composed of large, insoluble aggregates it is possibly not surprising that it does not leak from cells. Overall, however, it seems that we have comparatively little information on the...
important question of what happens to its iron content when the protein part of the ferritin molecule either leaves the intracellular environment or is degraded.

**In what form is serum ferritin measured?**

As mentioned previously, ferritin has an H and L form that are structurally interchangeable. Serum (L-)ferritin is usually measured with antibodies; only rarely is its iron content measured as well. Mass spectrometric methods, that can measure both protein and internal materials, may thus be expected to become the methods of choice.\(^{125-128}\) When such measurements are done, serum ferritin is usually found to contain some iron, but nothing like its full complement.\(^{91,92,97,129,130}\) This implies that it has lost it, whether during or after effluxing from the cells in which it originates.\(^{87}\)

**Is the protein component of serum ferritin benign or toxic?**

This question arises because if the iron has escaped and now (say) the inside of the ferritin is exposed in the serum it might have effects that the intact protein does not (given that the intact protein is extremely stable to thermal unfolding\(^ {75}\)). There is some fragmentary evidence that serum ferritin itself may have apoptotic and other actions on cells.\(^ {68,131,132}\) However, at present it is rather difficult to answer the question of how benign the protein-only form of ferritin (i.e. apoferritin) actually is, since serum ferritin does always tend to contain at least some iron, which can be released and is then not at all benign.

When the iron is varied systematically, it is iron-loaded ferritin that is the more toxic,\(^ {133}\) with apoferritin in fact being protective.\(^ {133-137}\) An important piece of evidence comes from the fact that homozygous ferritin knockout mice are embryo-lethal\(^ {138}\) but that heterozygous \(Fth^{+/C0}\) mice are fairly normal save that they have greatly increased levels of serum ferritin but unchanged serum iron.\(^ {139}\) This shows us, importantly, (i) that iron and ferritin can be regulated independently, and (ii) that excess ferritin protein is not of itself toxic \(in\) \(vivo\).\(^ {134}\) Hereditary hyperferritinemia-cataract syndrome is another disease in which serum ferritin is high but there is no evidence of systemic iron overload.\(^ {141-146}\) However, as well as (sometimes) being a marker of liver iron stores, serum ferritin is also an inflammatory marker, and there is often a considerable correlation between disease status and the serum ferritin protein level as measured using antibodies (which do not distinguish ferritins with varying iron content).

**Serum ferritin can be a marker of iron stores but is also an inflammatory biomarker**

What matters from the point of view of mammalian biology is both the total amount of iron and its speciation. While iron is necessary in every metabolising tissue, a substantial amount of iron is held in the liver, so ‘liver iron stores’ are often taken as the gold standard. Traditionally, these were measured in a biopsy, although this is not something that can be done with any frequency. Fortunately non-invasive measurement and imaging methods, \(e.g.\) neutron-stimulated emission controlled tomography,\(^ {147}\) SQUID-biosusceptometry\(^ {129,148}\) and (in particular) MRI \((e.g.\) ref. 149–158), also widely used for brain imaging \((e.g.\) ref. 159–161), are coming through. In some cases, where there is no inflammation and/or if a specific iron-related disease state is known, liver iron content can correlate with serum ferritin \((e.g.\) ref. 162 and 163), but more often the correlation is poor \((e.g.\) ref. 129, 157, 164–171). This is more or less inevitable when serum ferritin levels can be affected by two
largely independent causes, viz. iron status and inflammatory status. Thus, as mentioned above, serum ferritin alone is falling out of favour as a marker of iron status, with serum (‘soluble’) transferrin receptor (sTfR) being seen as much more useful, since sTfR may be used to distinguish the anaemia of chronic disease from iron-deficiency anaemia. In particular, the ‘sTfR Index’ (the sTfR/log ferritin ratio when both are measured in µg L⁻¹) is now considered to provide an estimate of body iron over a wide range of normal and depleted iron stores, and again is thus better for discriminating iron deficiency anaemia from the anaemia of chronic disease.\(^{176}\) In consequence, and especially in countries where inflammatory diseases are highly prevalent, it would seem that serum ferritin may in general be a better marker of inflammation than of iron status.

### Some diseases in which serum ferritin levels correlate with the presence or severity of disease

One of us has previously listed a great many (inflammatory) diseases in which iron dysregulation clearly plays a major role (e.g. ref. 15 and 17), but did not there distinguish serum ferritin explicitly. It is therefore helpful to set down some of the studies in which serum ferritin is known to associate with disease and/or disease severity, and this is done in Table 1.

There can be very little doubt that high serum ferritin levels accompany a great many diseases, and the corollary of this is that iron-induced hydroxyl radical formation leading to oxidative damage is likely to be a contributory factor in all of them. In addition, there are other useful phenotypic readouts that change with serum ferritin, and the next section describes one.

#### Table 1: A selection of diseases in which their presence or severity is known to be related to serum ferritin levels

<table>
<thead>
<tr>
<th>Disease or syndrome</th>
<th>Selected references</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute respiratory distress syndrome</td>
<td>181–184</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>185–189</td>
</tr>
<tr>
<td>Atherosclerosis</td>
<td>96, 190–200</td>
</tr>
<tr>
<td>Cancer</td>
<td>201–214</td>
</tr>
<tr>
<td>Cirrhosis of the liver</td>
<td>215–217</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>218–221</td>
</tr>
<tr>
<td>Diabetes mellitus, type 2</td>
<td>221–249</td>
</tr>
<tr>
<td>Hypertension</td>
<td>250–254</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>235, 236, 252, 255–272</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>273–276</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>277–285</td>
</tr>
<tr>
<td>Non-alcoholic fatty liver disease</td>
<td>260, 262, 264, 270, 286–301</td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>302–306</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>307–314</td>
</tr>
<tr>
<td>Sepsis/SIRS</td>
<td>315–318</td>
</tr>
<tr>
<td>Stroke</td>
<td>319–330</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>274, 331–342</td>
</tr>
</tbody>
</table>

Some morphological and related readouts of haematological changes associated with inflammatory diseases

While not the entire focus of this review, we highlight two other accompaniments to the unliganded iron caused by its loss from ferritin, namely morphological changes to both fibrin and erythrocytes. Thus, we have recently been developing the idea that many of the consequences of unliganded iron can be observed directly, by changes in properties such as erythrocyte (RBC) morphology and deformability and the nature and morphology of fibrin fibres generated in the presence of thrombin (as is observed in a number of diseases\(^ {141–146} \)). When thrombin is added to healthy whole blood, the RBCs will keep their typical discoid shape while fibrin fibres will form over and around the RBCs (such a typical healthy RBC (from an individual with a serum ferritin of 19 ng mL⁻¹), surrounded by fibrin is shown in Fig. 5A). However, in inflammatory conditions, where iron overload is present, the RBCs lose their typical discoid shape, while the fibrin network forms a dense matted layer.

![Fig. 5](image_url)

(A) Erythrocyte surrounded by fibrin network, from a healthy individual (serum ferritin (SF) = 19 ng mL⁻¹); (B) erythrocyte from a hereditary haemochromatosis individual (C282Y/C282Y) showing elongated shape with (in brown) matted fibrin (serum ferritin (SF) = 508 ng mL⁻¹); (C) erythrocyte of an individual with a pro-thrombin mutation (G20210A – heterozygous) as well as anti-phospholipid syndrome, showing fibrin forming a covering on the elongated erythrocyte (serum ferritin (SF) = 177 ng mL⁻¹); (D) erythrocyte from a high serum ferritin Alzheimer’s disease individual, showing architectural changes of the cell (serum ferritin (SF) = 256 ng mL⁻¹); E and F: whole blood smears (without added thrombin) (E) erythrocyte of hereditary haemochromatosis individual (serum ferritin (SF) = 508 ng mL⁻¹); (F) erythrocyte from hereditary haemochromatosis individual after addition of the iron chelator desferal (167 µM). Scale bar = 1 µm. Ethical clearance was obtained by E Pretorius for SEM analysis.
This was previously noted in RBCs of hereditary haemochromatosis, pro-thrombin mutation and antiphospholipid syndrome with increased serum ferritin levels and in high serum ferritin levels in Alzheimer’s disease. Fig. 5B–D show examples of RBCs and fibrin in these conditions. The corollary is clear, namely that these kinds of changes should be observable in cases where we see high serum ferritin, and some examples have already been published.

In the presence of iron, the already compromised RBCs are entrapped in the pathological fibrin masses. Iron plays an important role in the change of a netlike fibrin layer to a matted mass. We previously showed that healthy fibrin can be changed to resemble this matted appearance, when physiological levels of iron are added to plasma. Such matted fibrin morphology was also previously noted in type II diabetes, thrombotic ischemic stroke and systemic lupus erythematosus. Here the compromised RBCs twist around the fibres and this may cause a tight and rigid clot that might be particularly resistant to fibrinolysis.

As well as undergoing a shape change, the RBC membranes, in the presence of iron overload, also lose their elastic ability (deformability). This was noted in Alzheimer’s Disease individuals with iron overload, where their RBCs have a decreased membrane elasticity. A changed RBC membrane roughness was also noted in diabetes.

Further, RBC shape and membrane changes have been noted in smokers and in individuals with Chronic Obstructive Pulmonary Disorder (COPD). Both conditions are known to cause a general inflammatory state in the user as well as increased serum ferritin levels, and this may aid in the developing of the changed RBC deformability.

RBCs are extremely adaptable cells, particularly due to their rheological properties that force them to deform and reform under shear forces when they travel through narrow capillaries, while in the presence of high (poorly liganded) iron levels, they lose this deformability. By contrast, diseased RBCs can regain their discoid shape when selected chelators are added. Here we show how an RBC from a HH individual can return to the typical discoid shape after the addition of physiological levels of the iron chelator Desferal (Fig. 5E and F). This may have profound clinical implications under conditions where iron overload is present.

Thus, this unliganded iron affects (negatively) at least three things that can each contribute to vascular woes: erythrocyte morphology, erythrocyte deformability and fibrin structure/morphology.

Chelation for the reversal of iron-induced effects

The recognition that these changes can be reversed by known iron chelators leads to the recognition of a further prediction: that disease severity may be decreased through the use of iron chelators that may be pharmacological or nutritional. For the former, three iron chelators have been approved for clinical use (e.g. ref. 15, 360–364), viz. desferal/deferoxamine/desferrioxamine, L1/deferriprone and deferasirox. From the nutritional point of view, there is considerable evidence that many of the benefits of polyphenolic antioxidants (such as are found in coloured, and especially purple, fruits) derive from their ability to chelate unliganded iron (see e.g. ref. 17, 373–380).

Chemical kinetic basis of the relation of serum ferritin to liver iron stores and with disease

Many dozens of references indicate that in normal humans (without overt inflammation) serum ferritin levels are more or less closely related to body iron stores (e.g. in the liver) as judged by magnetic resonance imaging, biopsy or repeated phlebotomies. A selection of such references includes.

Since there is normally a decent correlation between body iron stores and serum ferritin, a series of simple (even first order) reactions in which cells release ferritin can account for this (Fig. 6). The question arises as to the nature of this ‘release’.

Ferritin transfer from cells to serum in humans: less active secretion, more simply leakage from damaged cells

Partly because a fraction of serum ferritin is glycosylated, as judged more or less solely by its ability to bind to concanavalin A (not a very specific assay), it is occasionally stated that ferritin is ‘secreted’ (e.g. ref. 382, 386 and 387), implying a controlled

A high-level systems approach to serum ferritin

Fig. 6 A high-level systems approach to serum ferritin. The diagram serves to illustrate why there tend to be correlations between the amount of ferritin in cells, the rate of its excretion by cell damage (involving liberation of unliganded iron) and the levels of serum ferritin. The serum ferritin correlates with disease but the cause is iron, with which it too can correlate. As with any systems biology network, multiple differences in different elements of the network can lead to the same overall effects, explaining the lack of a perfect correlation with any individual process. Thus a first order rate of efflux of ferritin is the product of (and thus contains contributions from) both the internal ferritin concentration and the rate constant for efflux, which may vary independently. For these purposes we do not discriminate the many individual iron species.
process, but without – so far as we are aware – any actual evidence for secretion rather than leakage being the mechanism in vivo. Indeed when ferritin is genuinely secreted, as it is for instance in insects, it has suitable leader (secretion signal) sequences, and mammalian ferritins do not.

This said, in cell cultures, there is some (scant) evidence for a comparatively small amount of regulated secretion, and one paper states that secretion can be decreased by brefeldin, an inhibitor of Golgi processes. This secreted form is said to be mainly the more acidic H form and is glycosylated. We note that both SCARAS and the transferrin receptor can act as receptors for serum ferritin, as can TIM-2 in mice, that can in some circumstances be taken up into cells. There is also evidence for active secretion (of a non-glycosylated form) in mice. Overall, however, there is not as yet any real evidence for regulated or active secretion in humans in vivo, such that the origin of serum ferritin must indeed largely, if not entirely, be seen as cellular damage. A number of analyses in the literature are consistent with this, and the following four sections pertain.

Relative lack of homeostasis of serum ferritin

The ‘normal range’ of a biochemical concentration is a body fluid is usually taken as the middle 95 percentiles. Somewhat like the Gini indices of economics, it is then possible to assess the ratio of particular percentiles, which gives an indication of the spread of these among populations. We shall call this ratio (of the 2.5th and 97.5th percentile) the 95 percentile ratio or 95PR. A small spread implies a tighter degree of regulation or control. The large normal range of serum ferritin (18–350 ng mL⁻¹) relative to other biochemical variables (http://www.globalrph.com/labs_def.htm#Ferritin_), with a 95PR of nearly 20, implies that it is not the subject of homeostasis, i.e. that its appearance is not regulated. One might also comment on the very low normal concentrations of serum ferritin (up to say 350 ng mL⁻¹ in men, up to say 150 ng mL⁻¹ in women) relative to say transferrin (1.88–3.41 mg mL⁻¹) (http://www.globalrph.com/labs_t.htm) or fibrinogen (2–4 mg mL⁻¹).

Association between serum ferritin and biomarkers of liver damage

As stated by Theil: “serum ferritin likely originates from cell leakage”. The figure in implies a similar role. Similarly, Hubel points out correlations between serum aspartate aminotransferase (a marker of hepatocellular damage) and SF, which again implies that serum ferritin originates from cellular damage. Many other authors (e.g. ref. 87, 91, 129, 288, 382 and 398) take a similar view. Serum alanine aminotransferase is another well known marker of liver damage that correlates with serum ferritin, consistent with the view that serum ferritin is indeed a marker of damaged cells. In this regard, it is worth noting that the rate of cell turnover, and especially liver cell turnover/regeneration, can be very high (e.g. ref. 408–411).

Correlation of serum ferritin with other markers of oxidative stress and hydroxyl radical formation

Since intracellular ferritin is a means of storing iron safely, and indeed its synthesis is increased in response to oxidative stress, one should not necessarily expect serum ferritin to be related to biomarkers reflecting hydroxyl radical formation via the Fenton reaction, that is catalysed by unliganded iron. However, in a similar vein to the liver damage above, serum ferritin levels do correlate with serum markers of hydroxyl radical formation such as 8-hydroxydeoxyguanosine, 27-hydroxycholesterol, 4-hydroxynonenal, isoprostanes, and malondialdehyde. Given that only unliganded iron can do this, the easiest interpretation of such data is that the serum ferritin has lost its iron and that it is this unliganded iron that catalyses hydroxyl radical formation and thus the production of these markers. An extensive food processing literature also documents this loss of iron from ferritin in muscle foods (e.g. ref. 437–439), where the consequent lipid oxidation is a major issue in causing rancid tastes, and where metal chelators decrease it.

Correlation of platelet microparticles with serum ferritin – further evidence for the cell damage hypothesis

As mentioned, a considerable number of papers note the presence of ferritin in erythrocytes, the largest cellular compartment in blood. In RBCs, one of the more notable cell death mechanisms is eryptosis, a suicidal death of erythrocytes; this is characterized by erythrocyte shrinkage, blebbing, and phospholipid scrambling of the cell membrane. There is limited evidence that eryptosis occurs in iron overload conditions like β-thalassemia. It is noteworthy that erythocyte-derived microparticles are also often observable in the blood of patients with diseases associated with high serum ferritin levels (Table 1). These microparticles are circulating fragments derived from blebbing and shedding of cell membranes through several mechanisms that include activation, apoptosis (in nucleated cells) and cell damage. These microparticles are well-known in cardiovascular, neoplastic, and inflammatory diseases and this again implies a correlation between cellular damage and serum ferritin. Cell damage also releases both phospholipids and DNA, and (in a similar vein) ferritin levels are also raised in diseases in which antibodies to such molecules are also present (e.g. ref. 455–457).

Summarising remarks

Although serum ferritin is widely seen as an inflammatory biomarker, our understanding of its role as an intracellular iron storage protein gives no explanation of why it should even exist in serum. The view summarised here is that serum ferritin leaks from damaged cells, losing most of its iron on the way, and leaving that iron in an unliganded form that can impact negatively on health. This unliganded iron can of course stimulate further cell damage. This overall view serves straightforwardly to explain the following, known observations.
(1) Serum ferritin exists, despite the fact that ferritin is not synthesised in the serum.
(2) Serum ferritin lacks most of the iron it contained when intracellular.
(3) The intracellular ferritin must have ‘dumped’ its unliganded iron somewhere, where it can participate in Haber–Weiss and Fenton reactions, creating hydroxyl radicals and consequent further cellular damage.
(4) The serum ferritin protein is itself considered benign.139
(5) Yet the level of serum ferritin correlates with numerous inflammatory and degenerative diseases.

Quo vadis (where next)? A perspective for future work

We consider the summary presented here rather persuasive, as it has considerable explanatory power in terms of accounting for the nature and consequences of serum ferritin, and providing corollaries of the fact that it has largely ‘lost’ its iron that are borne out by evidence. It also leads us to note some of the experiments that need to be done. First, we need to understand much better the state of both cellular and serum ferritin in terms both of its subunit composition and the nature and extent of its iron content. We also need to understand better the different cellular and tissue distributions of the variously loaded forms, and we certainly need to determine the toxicity displayed, or protection afforded, by the different forms of well characterised ferritins under different circumstances. Far from implying that serum ferritin is a poor biomarker, it leads us rather to suggest that we need to follow it (and its sequelae) more carefully and longitudinally during the development or otherwise of various diseases, and to test how well its changes reflect therapeutic benefits to disease progression. Only then will we determine its true utility, whether alone or in combination with other biomarkers.

Acknowledgements

We thank Dr Steve O’Hagan for considerable assistance with a number of the figures, and Janette Bester for the preparation of the samples for SEM analysis.

References

4 X. Tang and B. Zhou, Ferritin is the key to dietary iron absorption and tissue iron detoxification in Drosophila melanogaster, FASEB J., 2013, 27, 288–298.
17 D. B. Kell, Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples, Arch. Toxicol., 2010, 577, 825–889.


100 Y. Zhang, M. Mikhail, D. Xu, Y. Li, S. Soe-Lin, B. Ning, W. Li, G. Nie, Y. Zhao and P. Ponka, Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit, *Antioxid. Redox Signaling*, 2010, 13, 999–1009.


118 K. L. Double, M. Gerlach, V. Schunemann, A. X. Trautwein, L. Zecca, M. Gallorini, M. B. Youdim, P. Riederer and...


167 P. D. Jensen, F. T. Jensen, T. Christensen, J. L. Nielsen and J. Ellegaard, Relationship between hepatocellular injury and transfusional iron overload prior to and during iron


170 A. Kolnagou, K. Natsiopoulos, M. Kleanthous, A. Ioannou and G. J. Kontoghiorghes, Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*, *Toxicol. Mech. Methods*, 2013, **23**, 48–56.


219 K. C. Sung, S. M. Kang, E. J. Cho, J. B. Park, S. H. Wild and C. D. Byrne, Ferritin is independently associated with the


242 B. Batchuluun, T. Matsumata, N. Erdenebileg, G. Tsagaantsooj, K. Boldbaatar and A. Khasag, Serum ferritin level is higher in poorly controlled patients with Type 2 diabetes and people without diabetes, aged over 55 years, *Diabetic Med.*, 2013, DOI: 10.1111/dme.12343.


244 C. H. Jung, M. J. Lee, J. Y. Hwang, J. E. Jang, J. Leem, J. Y. Park, J. Lee, H. K. Kim and W. J. Lee, Elevated serum ferritin level is associated with the incident type 2 diabetes


337 K. Vanarsa, Y. Ye, J. Han, C. Xie, C. Mohan and T. Wu, Inflammation associated anemia and ferritin as disease markers in SLE, Arthritis Res. Ther., 2012, 14, R182.


347 J. Best, T. V. Buys, B. Lipinski, D. B. Kel and E. Pretorius, High ferritin levels have major effects on the morphology


402 T. Nakagawa, Y. Muramoto, M. Hori, S. Mihrara, T. Marubayashi and K. Nakagawa, A preliminary investigation of the association...


435 T. E. de Jesus dos Santos, G. F. de Sousa, M. C. Barbosa and E. A. Decker and B. Welch, Role of ferritin as a lipid
438 J. I. Gray, E. A. Gomaa and D. J. Buckley, Oxidative quality

